comparemela.com
Home
Live Updates
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn : comparemela.com
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn
In animal studies, deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein was observed. Plan to submit IND and initiate Phase 1 study in... | September 28, 2022
Related Keywords
Chau Cheng ,
Pete Salzmann ,
Demyelinating Polyneuropathy ,
Exchange Commission ,
Immunovant Inc ,
Nasdaq ,
Globenewswire Inc ,
Investor Day ,
Investor Relations ,
Chief Executive Officer ,
Myasthenia Gravis ,
Thyroid Eye Disease ,
Chronic Inflammatory Demyelinating Polyneuropathy ,
Grave Disease ,
Warm Autoimmune Hemolytic Anemia ,
Private Securities Litigation Reform Act ,
Annual Report ,
Immunovant ,
Nc Stock Exchange ,
News ,
Information ,
Press Release ,
N ,
Animal ,
Jeep ,
Egg ,
Cowering ,
Similar ,
O ,
Batoclimab ,
Ith ,
Dr ,
Albumin ,
End ,
Lipoprotein ,
Gas ,
Plan ,
Ubmit ,
Nitiate ,
Hase ,
,
Tudy Imvt Us45258j1025 ,
comparemela.com © 2020. All Rights Reserved.